GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: emapalumab-lzsg | Gamifant® | NI-0501 | NI0501
                                 emapalumab is an approved drug (FDA (2018)) Compound class: 
                                                            Antibody
                                 
                                    
                                        Comment: Emapalumab (NI-0501) is a fully human monoclonal antibody that targets interferon gamma (IFNγ). Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent WO2006109191, and in which NI-0501 is confirmed as an exemplary antibody [2]. | 
| Classification  | |
| Compound class | Antibody | 
| Approved drug? | Yes. US FDA (2018) | 
| International Nonproprietary Names  | |
| INN number | INN | 
| 10319 | emapalumab | 
| Synonyms  | 
| emapalumab-lzsg | Gamifant® | NI-0501 | NI0501 | 
| Database Links  | |
| Specialist databases | |
| IMGT/mAb-DB | 666 | 
| Other databases | |
| GtoPdb PubChem SID | 318164814 | 
| Search PubMed clinical trials | emapalumab | 
| Search PubMed titles | emapalumab | 
| Search PubMed titles/abstracts | emapalumab |